author-photo

Toshihiro Nukiwa

Tohoku University

447

Papers

19181

Citations

Citation Trend

Filter By

Papers (324) Sort By

Journal Conference Others

Overall Survival Analysis of Bevacizumab Plus Erlotinib for Advanced EGFR -Mutant Metastatic NSCLC

2021 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Pirfenidone Delays the Prescription of Concomitant Drugs in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Japanese Phase III Clinical Trial

2020
Show All
- Source
- Cite
- Save
Citations (0)
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (30)
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.

2020 EBioMedicine
Show All
- Source
- Cite
- Save
Citations (10)
Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Diagnosis and treatment of new idiopathic interstitial pneumonias cases: Analysis using the Japanese Registry

2020 European Respiratory Journal
Show All
- Source
- Cite
- Save
Citations (0)
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

2020 Respiratory Research
Show All
- Source
- Cite
- Save
Citations (3)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (114)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (220)